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Abstract 
Paratuberculosis (PTB), a chronic granulomatous enteritis produced by Mycobacterium avium subspecies paratubercu-
losis (MAP), is considered as one of the diseases with the highest economic impact in the ruminant industry. Vaccina-
tion against MAP is recommended during the first months after birth on the basis that protection would be conferred 
before the first contact with mycobacteria. However, little is known about the therapeutic effect of MAP vaccination in 
controlled experimental conditions. The current study was designed to evaluate the efficacy of vaccination before and 
after challenge with MAP in a rabbit infection model. The rabbits were divided into four groups: non-infected control 
(NIC, n = 4), infected control challenged with MAP (IC, n = 5), vaccinated and challenged 1 month after with MAP 
(VSI, n = 5) and challenged with MAP and vaccinated 2 months later (IVS, n = 5). The results from this study show a 
quick increase in IFN-γ release upon stimulation with bovine, avian and johnin PPD in animals vaccinated before MAP 
challenge. All vaccinated animals show an increased humoral response as seen by western blot and ELISA. The final 
bacteriology index (considering tissue culture and qPCR) shows that the IC group was the most affected. Vaccina-
tion after infection (IVS) produced the lowest bacteriology index showing significant differences with the IC group 
(p = 0.034). In conclusion, vaccination against MAP shows positive effects in a rabbit model. However, vaccination 
after infection shows a slightly stronger protective effect compared to vaccination before infection, suggesting a 
therapeutic effect. This feature could be applied to previously infected adult animals under field conditions.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Paratuberculosis (PTB) also called Johne’s disease is a 
chronic granulomatous enteritis produced by Mycobac-
terium avium subspecies paratuberculosis (MAP) that 
mostly affects ruminants. PTB considered as one of the 
diseases with the highest economic impact in the rumi-
nant industry can affect many ruminant and non-rumi-
nant wildlife species, as well [1, 2]. In addition numerous 
studies have suggested that MAP could play a role in 
human Crohn’s Disease [3–5].
PTB is transmitted predominantly through the fecal-
oral route. Infected animals in the subclinical stage shed 
MAP in the environment intermittently, making its 
control difficult. Current control programs in livestock 
include test and cull strategies whose implementation 
alone is not sufficient to control the disease making vac-
cination the best intervention strategy [6, 7]. Vaccina-
tion against MAP reduces the incidence of PTB within 
herds and the severity of disease in individual animals. In 
general, it reduces production loss, mortality and histo-
pathological lesions [8, 9] and it diminishes the number 
of clinical cases in cattle, reducing bacterial shedding in 
feces contributing to longer productive life and improve-
ment in milk production [10–12]. In small ruminants, 
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vaccination has been successfully used as a part of the 
control programs in sheep in Iceland [13] and Australia 
[14] and in goats in Norway [15] and Spain [16] allowing 
a sharper decline in PTB prevalence. However, the fact 
that vaccination does not provide complete protection 
from infection is also widely accepted [17, 18].
Vaccination against MAP is recommended during 
the first months after birth on the basis that protec-
tion would be conferred before the first contact with 
the mycobacteria [6, 15, 19]. Nevertheless, due to the 
chronic nature of MAP infection when clinical signs are 
detected vaccination of the whole flock independent of 
age, including adult animals can be an option [12]. In 
fact, studies involving vaccination after MAP infection 
have shown reduction of MAP burden in sheep vacci-
nated with Gudair® [20] or with a live attenuated vaccine 
[21]. Although the mechanism of this therapeutic effect is 
unknown it can be assumed that whole herd vaccination 
might contribute to a reduction in the level of environ-
mental contamination with MAP allowing faster progress 
in PTB control.
The therapeutic effect of vaccines could be very useful 
controlling the spread of infectious diseases in which the 
number of individuals in a latent or subclinical stage of 
infection is high. A recently published systematic review 
has reported that some vaccines against tuberculosis 
currently under study have a therapeutic effect even in 
latent infection [22]. When it comes to PTB, vaccina-
tion effects after MAP exposure have been understud-
ied in experimental conditions, probably because of the 
lengthy incubation period of PTB in ruminants. In this 
sense, rabbits which are naturally susceptible to infec-
tion with MAP [23–25] and have shown to be useful 
short term models in experimental conditions as well 
[26], may be suitable to study the therapeutic effect of 
PTB vaccination.
The aim of this study, therefore, was to evaluate the 
effect of vaccination with a heat inactivated vaccine pre-
vious to and after challenge with MAP in a rabbit infec-
tion model resembling the subclinical stage of PTB, 




New Zealand white female rabbits (n  =  19) were pur-
chased from official dealers and arrived at the NEIKER 
animal facilities at the age of 6  weeks 1.5  kg weight to 
follow a 2  week adaptation period. The most impor-
tant aspects of the experimental design are represented 
in Figure  1. The rabbits were divided into four groups: 
non-infected control (NIC; n = 4), infected control (IC; 
n = 5), infected and then vaccinated with Silirum® (IVS; 
n  =  5) and vaccinated with Silirum® prior to infection 
(VSI; n = 5). Silirum® is a heat-inactivated vaccine con-
taining 2.5 mg/mL of MAP strain 316F culture combined 
with an immunological adjuvant consisting of highly 
refined mineral oil.
At day 1 of experimentation, animals were sedated 
with azepromazine maleate intramuscularly at 2  mg/
kg of weight and tattooed in the inner part of one of the 
ears for easier identification during the experiment. Also, 
on this day, the VSI group rabbits were vaccinated sub-
cutaneously with 1  mL of Silirum®. On three consecu-
tive days (days 28, 29 and 30) all animals except the ones 
belonging to the NIC group were challenged orally with 
109 CFU of MAP strain K10 obtained as described previ-
ously [26]. Rabbits of the IVS group were vaccinated with 
Silirum® 71  days after the beginning of the experiment 
that is, 41 days after challenge.
Animals were monitored by recording weight and 
blood prior to vaccination (baseline S0 samples) and after 
challenge twice a month (S1–S10). The fecal consistency 
was observed in all samplings. Feces were collected after 
challenge (S0A) and freshly processed. Blood samples 
were divided for IFN-γ release quantification and for 
serological testing. In this case, blood was centrifuged at 
1500 g for 10 min to obtain plasma which was stored at 
−20 °C until ELISA or Western blot (WB) analyses were 
performed.
Figure 1 Experimental design diagram. S: sampling, N: necropsy, IC: infected control, VSI: vaccination before infection, IVS: vaccination after 
infection.
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The endpoint of the experiment was set at day 205 and 
all animals were euthanized administering pentobarbi-
tal intracardially after deep sedation with xilazine and 
ketamine. Then a complete necropsy focusing on a gross 
pathology in the digestive tract was performed and tis-
sue samples were collected and stored at −20  °C. Han-
dling procedures, sampling frequency and euthanasia 
procedure were designed to produce minimum stress 
on subjects following European, National and Regional 
Law and Ethics Committee regulations. The experiment 
was reviewed and approved by NEIKER’s Animal Care 
and Use Committee and by the Agriculture Department 
(PARAMOD-6278-BFA).
Tissue MAP culture
For culture, 2 g of collected tissues were processed. Ton-
sils, spleen, liver, muscle and mesenteric lymph node 
were spliced in tiny pieces and weighed, whereas, vermi-
form appendix, sacculus rotundus, ileum and jejunum 
were scraped for mucosa and weighed and samples were 
processed for HEYM [27] as described in Arrazuria et al. 
[26]. For culture on 7H9 OADC [28] supplemented with 
MJ penicillin, anfotericin and cloramphenicol, the same 
decontaminated suspension used for HEYM culture was 
centrifuged at 2885  g during 10  min. Supernatant was 
discarded and a wash with sterile water was performed. 
After a new centrifugation step in the same conditions 
the pellet was suspended in 2  mL of water and four 
drops/tube were seeded. All seeded tubes were incubated 
at 37 ± 1 °C and checked for MAP growth at 8, 12, 16 and 
20 weeks.
Fecal and tissue DNA extraction
Feces and tissue DNA was extracted with DNA Extract-
VK (Vacunek S.L, Derio, Spain) according to the manu-
facturer’s instructions with slight modifications that 
included an initial hydrating step where 1  g of feces 
was hydrated with 7  mL of sterile water overnight. The 
following day, the mixture was vortexed to achieve a 
homogenous solution and let still for 10–15  min. Then 
500 µL of supernatant were pipetted into a new vial and 
centrifuged at 11  000  g for 5  min. The supernatant was 
discarded and the pellet was suspended in 250 µL of ster-
ile water. From this step on, the manufacturer’s instruc-
tions were followed.
Collected tissues (tonsils, spleen, liver, muscle, mesen-
teric lymph node, vermiform appendix, sacculus rotun-
dus, ileum and jejunum) and cecal content stored at 
−20 °C were thawed overnight at 4 °C and brief modifica-
tions were performed as previously described [26].
In both cases extracted DNA was stored at −20 °C until 
PCR were performed.
MAP PCR. Detection and quantification
For initial screening purposes a real time multiplex PCR 
detecting IS900 and ISMap02 DNA sequences of MAP 
was performed with 350  ng/μL as described by Sevilla 
et al. [29].
PCR results were analyzed using the 7500 System SDS 
software v. 1.4 (Applied Biosystems, Spain). Threshold 
cycle (CT) and baseline were automatically determined 
by the software and verified by visual examination of the 
threshold line in amplification plots. CT values equal or 
below 38 for both IS900 and ISMap02 probes were con-
sidered positive, CT values over 38 for both targets probe 
and under 38 for IAC probe were considered negative.
For a quantitative assessment of MAP levels in tis-
sues, this is genomic equivalents (GE), qPCR was done 
employing ParaTB-Kuanti-VK (Vacunek S.L, Derio, 
Spain), and the manufacturer’s instructions were fol-
lowed. Briefly, 10  µL of DNA were added to 15  µL of 
master mix in 96 well plates. Triplicates of dilutions of 
positive control standards were run in parallel to obtain 
data points for standard curves. Amplification and real 
time measurement were performed in a 7500 Real Time 
PCR System (Applied Biosystems, Spain). The results 
were analysed with the ABI Prism software version 7500 
SDS software v 1.4.
Interferon gamma release assay (IGRA)
To explore the cellular immune response, interferon 
gamma release quantification was carried out after stim-
ulation of whole blood with bovine, avian and johnin 
purified protein derivative (PPD) (CZ Veterinaria, Por-
riño, Spain). Heparinized blood samples collected at S0, 
S1, S3 and S10 were assayed. Stimulation of whole blood 
was performed within 8 h of collection. A 25 000 UI/mL 
concentrations of bovine and avian PPD and 26 446 UI/
mL of johnin PPD were used.
Briefly, 35  µL of different PPD (10  µg/mL) or sterile 
PBS 0.01 M pH 7.2 used as a negative control were added 
to 500 µL of whole blood from each animal. All samples 
were mixed slowly and incubated at 37 °C and 5–7% CO2 
for 16–24  h. Plasma was separated by centrifugation at 
500 g for 10 min and frozen at −20 °C until testing. The 
IFN-γ production was measured using a commercial kit 
(Cusabio-Biotech®, China) according to the manufactur-
er’s instructions.
The optical density was determined at 450 and 570 nm 
to correct for optical imperfections in the plate, using 
an automated ELISA plate reader (Multiskan EX®, 
Thermo Lab Systems, Finland). The standard curve was 
performed to calculate the IFN-γ concentration of each 
sample. The final IFN-γ concentration was obtained by 
subtracting the values of the negative control (sterile 
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PBS) from each tested PPD in order to reduce the back-
ground of non-specific IFN-γ release.
PPA‑3 enzyme‑linked immunosorbent assay (ELISA)
Homemade indirect ELISA was performed using PTB 
protoplasmatic antigen 3 (PPA-3) (Allied Lab, Fayette, 
Missouri, USA). Plasma samples were adsorbed with 
Mycobacterium phlei in saline solution (5  g/L) at equal 
concentrations to reduce cross-reactivity. Checkerboard 
titration was performed to determine the optimal con-
centrations of plasma (1:200) and conjugate (0.15 µg/mL) 
(unpublished data).
Microtiter plates were coated with 0.04  mg/mL of 
PPA-3 diluted in 0.5% sodium carbonate buffer (pH 9.6). 
A total of 100 µL of antigen dilution was added to each 
well and it was incubated at 4  °C overnight. After coat-
ing, the wells were washed once with 0.05% Tween 80 in 
0.85% sodium chloride (Wash solution).
The plasma samples were diluted 1:200 in 0.05% Tween 
80 in PBS (PBS-T) and were assayed (100 µL/well). After 
2 h of incubation at RT in a humid chamber, plates were 
washed three times with 300  µL/well of wash solution. 
A volume of 100  µL of recombinant protein G peroxi-
dase (0.025 µg/mL, Sigma-Aldrich, Spain) in PBS-T was 
added to each well and the plates were incubated at RT 
for 2  h. The plates were washed again three times with 
300  µL/well of wash solution and then 100  µL/well of 
peroxidase substrate (0.01% ABTS, Sigma Aldrich, Spain) 
were added. The plates were incubated at RT for 30 min 
in darkness. The reaction was stopped by the addition of 
100 µL/well of 2% hydrofluoric acid. The absorbance was 
measured at 405 and 450 nm using an automated ELISA 
plate reader (Multiskan EX®, Thermo Lab Systems, 
Finland).
The reading obtained at 450  nm was subtracted from 
the reading of 405 nm to reduce optical imperfections in 
the plate. The results are expressed as a relative absorb-
ance index calculated by dividing the mean absorbance 
of the sample by the mean absorbance of a negative 
sample. Optical density (OD) values were normalized 
across plates using the following calculation: Absorbance 
index = (Mean sample OD) × (Mean OD of all positive 
control plates/Mean OD of the positive control plate).
Sds‑page
K10 strain proteins were obtained and separated by SDS-
PAGE 12%. For protein extraction 50 mL (approximately 
1.5  mL of cell pellet) of MAP K10 strain culture at log 
phase was centrifuged at 3000 g 10  min. The superna-
tant was discarded and the pellet was washed three times 
with PBS 0.01 M. The pellet was resuspended in 300 µL 
of complete extraction buffer containing 15  µL of DTT 
(dithiothreitol), 12  µL of IP25 (Protease inhibitor 25x) 
and 273 µL of extraction buffer. The extraction buffer was 
composed of Tris 0.04  M, Urea 8  M and Chaps 0.01  M 
in Ready Prep proteomics Grade Water (Bio-Rad Labo-
ratories, Spain). This suspension was added to tubes with 
300  mg of glass beads and homogenized at 30  Hz dur-
ing 10 min on TissueLyser II (Qiagen, Spain). Following 
homogenization, centrifugation at 15 000 g during 15 min 
was performed and the supernatant was transferred to a 
new vial. The absorbance was measured at 280 nm in a 
NanoDrop® ND-1000 Spectrophotometer (Thermo sci-
entific, Spain).
For protein separation, 200  µg of K10 strain proteins 
were loaded in 12% acrylamide gels, and separation by 
electrophoresis was performed at 150  V. Precision Plus 
Protein™ Dual Color Standard (Bio-Rad Laboratories, 
Spain) was loaded in one lane to monitor electrophoretic 
separation, transfer efficiency as well as molecular weight 
size.
Protein transfer
The membrane protein transfer was performed accord-
ing to the guidelines outlined by Towbin [30]. Briefly, 
proteins were transferred to polyvinylidene fluoride 
(PVDF) microporous membrane, Immobilon® (Mil-
lipore Ibérica, Madrid, Spain) by Trans-Blot® Semi-
Dry electrophoretic transfer cell (Bio-Rad Laboratories, 
Spain) at 15 V.
Western blot (WB)
The membrane was cut in 0.5  cm wide strips that were 
blocked with 0.1  M Tris-Buffered Saline (TBS) supple-
mented with 5% nonfat dry milk (TBS-M) overnight at 
4 °C.
Plasmas were diluted 1:50 in TBS-M prior to incuba-
tion with the membrane for 1 h at 37 °C with slow agita-
tion. After four five minute washes with TBS, membranes 
were incubated with recombinant protein G peroxidase 
(Sigma-Aldrich, Spain) 1:8000 in TBS-M for 1 h at 37 °C. 
The membrane was washed again four times with TBS 
and enhanced chemiluminescence (ECL) was added. The 
immunoreactive bands were visualized by autoradiog-
raphy. After scanning the autoradiography, reactivities 
were measured with Image J software.
Statistical analysis
Significance of the differences among groups for all vari-
ables weight, fecal PCR, MAP tissue PCR, IFN-γ release 
increase index, ELISA index, western blot reactivity, 
bacteriology index were assessed using analysis of vari-
ance (ANOVA). Some variables were based on summary 
measures obtained as follows; weight gain: the difference 
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between S10 and S0 weight, total MAP in tissues: the 
sum of MAP GE/g in all examined tissues, ELISA index: 
the difference between S10 and S0 index, Western blot 
reactivity: the sum of the total reactivity per area for each 
protein measured with Image J. Non- normally distrib-
uted data were subjected to natural log(Ln) transforma-
tion prior to statistical analyses. When ANOVA showed 
significant differences, Tukey’s post hoc testing was used 
to make paired comparisons. Pearson’s correlation test 
was applied to assess the association between ELISA and 
total western blot reactivity.
IFN-γ response was expressed for each sampling time 
1, 3 and 10 (S1, S3, S10) after subtracting the start point 
sampling (S0). In order to estimate the contribution of 
vaccination to IFN-γ release, an index was calculated, 
where mean values from non-vaccinated infected ani-
mals were subtracted from the value of each vaccinated 
and infected animal and divided by the value of each 
vaccinated and infected animal. Afterwards, ANOVA 
was performed. The percentage of these indexes may be 
assumed to be equivalent to the response conferred by 
vaccination.
In order to take into account both bacteriological out-
comes, the results of both post-mortem bacteriological 
techniques (qPCR of tissues and tissue culture) were used 
to generate what was termed as the bacteriology index. 
For this purpose, the number of positive qPCR tissues 
and culture were placed on the same scale by dividing 
each category by the maximum value within the category. 
The sum of the two resulting values for each technique 
was the final bacteriology index for each animal.
All statistical analyses were performed using R statisti-
cal software (3.1.0) and differences among groups for all 
variables were stated at p < 0.05.
Results
In vivo follow up
All animals maintained a healthy status until the experi-
ment endpoint except for one animal belonging to the 
VSI group. This animal was euthanized prematurely at 
153 days after the beginning of the experiment due to an 
unrelated pathology.
Challenge was achieved in all animals as shown by 
equal shedding levels in all animals from the third day 
challenge fecal sampling (p = 0.373). No episodes of diar-
rhea were observed throughout the experiment. How-
ever, fecal consistency did vary from hard to soft pellets 
occasionally in some animals.
Animals maintained normal food intake and only 
minimal weight loss was observed in some occasions in 
individuals that eventually recovered from the losses. Sig-
nificant differences in weight gain among groups were 
not observed (p = 0.302).
Cellular immune response: interferon gamma release assay
As expected, animals from the NIC group did not show 
an increase of IFN-γ levels with any of the studied PPD 
and in the IC group, slightly higher IFN-γ levels were 
observed in the first sampling after challenge with all 
tested PPD (data not shown). In order, to measure the 
effect of vaccination on the cellular immune response the 
percentage of IFN-γ levels due to vaccination were calcu-
lated and represented on Table 1. These percentages were 
superior for the VSI group compared to the IVS group 
upon stimulation with all PPD at all time points show-
ing significant differences at S10 upon stimulation with 
johnin (p = 0.0019).
Humoral immune response
The antibody production against MAP was assessed by 
PPA3 ELISA and WB. The results of antibody produc-
tion expressed as the means of the ELISA Index values 
of all study groups during the experiment are repre-
sented in Figure  2. Vaccination with Silirum® produced 
an increase in humoral immune response prior to chal-
lenge (VSI vs IC; p  =  0.005) and also after challenge 
(IVS vs IC; p = 0.001). However, infection alone did not 
raise humoral response, at least during the experimental 
period (NIC vs CI; p = 0.999). Vaccination prior to chal-
lenge produced slightly higher levels of antibodies com-
pared to vaccination after challenge; however, at the end 
of the experiment the level of antibodies was similar in 
both vaccination schemes (Figure 2).
WB results are shown in Figure  3. We did not find 
any differences in humoral response against MAP pro-
teins between infected and non-infected animals in 
both assays. The reactivity per area which was measured 
Table 1 Percentage of IFN-γ release index upon stimula-
tion with PPD due to vaccination
AV: Avian PPD, BO: bovine PPD, JO: johnin PPD, VSI: vaccinated before infection, 
IVS: vaccinated after infection, S1: IFN-γ release index first sampling. S3: IFN-γ 
release index third sampling, S10: IFN-γ release index tenth sampling.
* p < 0.05.
a Index percentage in relation to the infected control group (VSI-IC)/VSI.
b Index percentage in relation to the infected control group (IVS-IC)/IVS.
PPD VSIa IVSb p value
S1 AV 54.56 0.00 0.172
BO 60.97 0.00 0.139
JO 64.66 0.00 0.296
S3 AV 94.21 62.68 0.969
BO 0.00 1.27 0.111
JO 62.09 54.59 0.925
S10 AV 100.00 100.00 0.404
BO 100.00 100.00 0.431
JO 33.21 0.00 0.0019*
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attending to the protein weight did show differences 
when vaccinated animals were compared with infected 
ones, as well as between both vaccinated groups. 
Humoral response against ~22  kDa protein was signifi-
cantly higher in both vaccinated groups, vaccinated after 
challenge (IVS vs IC, p =  0.007) and vaccinated before 
challenge (VSI vs IC, p  <  0.0001). The VSI group also 
had higher antibody levels against ~22 kDa than the IVS 
group (p < 0.0001). Animals vaccinated before challenge 
(VSI) had higher levels of antibodies against ~35  kDa 
proteins than those of the infected group (VSI vs IC, 
p  <  0.0001) or those vaccinated after challenge (VSI vs 
IVS, p < 0.0001). Vaccinated animals after infection (IVS) 
showed higher reactivity against ~37 kDa protein than IC 
animals (p = 0.008). Regarding humoral response against 
~75 kDa proteins the animals vaccinated before infection 
(VSI) had higher values than IC animals (p = 0.030) and 
the IVS group animals (p = 0.014).
The total reactivity per group in WB had a strong 
positive correlation with the ELISA assay (r  =  0.993; 
p = 0.006).
Post mortem findings
A summary of postmortem findings is shown in Table 2. 
At necropsy, some infected animals presented gross 
pathology consisting of increased vascularity and pale-
white reactive spots in the sacculus rotundus and 
vermiform appendix as well as wall thickening in the 
ileum and jejunum compatible with PTB.
MAP was isolated from the sacculus rotundus, vermi-
form appendix, ileum and/or mesenteric lymph node in 6 
of the 14 infected animals. In the IC group, MAP was iso-
lated from at least one tissue in 80% of the animals. Vac-
cination decreased the bacterial burden in tissues. MAP 
was not isolated from any tissue of animals belonging to 
the IVS group whereas two animals of the VSI group pre-
sented one MAP positive tissue culture each.
If we attend to bacterial load measured by qPCR, we 
detected MAP DNA in the sacculus rotundus, vermi-
form appendix and mucosa. In the IC group, all animals 
had at least one tissue positive for qPCR with a mean of 
150 ± 87 GE/g of MAP. Vaccination decreased the num-
ber of positive tissues for MAP qPCR. MAP DNA was 
detected in at least one tissue in 40% of the animals from 
the IVS group while 50% of the animals of the VSI group 
presented positive results to qPCR. However, bacterial 
load in the IVS group was higher than in the VSI group 
(953 ± 375 GE/g of MAP, 94 ± 71 GE/g of MAP respec-
tively) although significant differences were not observed 
among the vaccinated groups.
The bacteriology index considering the number of posi-
tive tissues for qPCR and the number of tissues in which 
MAP has been isolated is represented in Figure  4. Ani-
mals of the IC group had the highest values followed by 
Figure 2 Evolution of mean ELISA index value per group. NIC: non infected control, IC: infected control, IVS: vaccination after infection, VSI: 
vaccination before infection. Error bars represent standard error of the mean.
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animals vaccinated before infection (VSI). Vaccination 
after infection (IVS) produced the lowest bacteriology 
index showing significant differences with the IC group 
(p = 0.034).
Discussion
The present study attempts to characterize the effect of 
vaccination before and after MAP challenge in a rabbit 
infection model. To our knowledge this is the first time 
that vaccination against PTB has been evaluated in a rab-
bit model, showing an increased immune response and 
reducing bacterial burden in tissues.
All challenged animals had equal chances of being 
infected due to the absence of significant differences in 
shedding levels in the fecal sampling immediately after 
challenge. As in previous studies carried out by our 
group with this short term model, clinical signs were not 
observed representing the subclinical stage of infection 
[26]. In order to observe clinical symptoms the experi-
ment should have gone on for a longer period of time: 
5–8  months for diarrhea [31, 32] and up to 2  years for 
emaciation [33].
PTB whole cell vaccine studies have demonstrated the 
induction of both cellular and humoral immune response 
in calves [34–37], sheep [38, 39] and goats [40]. For this 
reason we have attempted to evaluate both: cellular by 
IFN-γ release and humoral by ELISA and Western blot. 
Animals vaccinated before infection (VSI) had a tempo-
rary increase in IFN-γ response (at S1 or 42 days after the 
beginning of the experiment) although significant differ-
ences were not observed, probably due to the high vari-
ability between animals (non-reactors, low-reactors and 
high reactors) and in turn by the small sample number. 
These results are supported by previous studies in which 
vaccination with a whole cell vaccine increased IFN-γ 
and IL-10 release, in a murine model [41]. In addition, 
Figure 3 Western Blot of serum of individual animals showing reactivity to MAP K10 extracted proteins. A Non-infected control (NIC), 
B Infected control (IC), C Vaccinated after infection (IVS), and D Vaccinated before infection (VSI). Strips were incubated with serum dilution 1:50. 
Recombinant protein G peroxidase was used at dilution 1:8000. Blots were developed by chemiluminescent detection and visualized by autoradi-
ography. Samplings (S0, S1, S4 and S10) of each animal are represented.
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in this group (VSI), significant differences between IFN-
γ release levels upon stimulation with bovine and avian 
PPD were not observed as documented in previous stud-
ies [34, 42, 43].
The effect of vaccination after challenge in the cel-
lular immune response is not clear, at least on the short 
term basis. The IVS group was vaccinated at S3 (71 days 
of the start point of the experiment) and IFN-γ response 
was measured at S10 (128 days after vaccination). In this 
period of time IFN-γ response could have increased tem-
porarily and decreased shortly afterwards, and we would 
not have detected these oscillations at S10. Also, the 
effect of vaccination itself prior to challenge was missed 
since a proper sampling was not performed between vac-
cination and challenge in the VSI group. For this reason, 
calculating the index in relation to infection was the only 
way to estimate the contribution of vaccination on IFN-γ 
release at each sampling time point. The VSI group pre-
sented higher percentages of IFN-γ index in compari-
son to the IVS group meaning that on a long term basis 
vaccination prior to infection may be more effective in 
maintaining a cellular immune response. In any case, 
differences between both groups were only significant 
for johnin PPD at the final sampling point, so we can-
not state if there was any difference in the specificity of 
cellular immune response related with the sequence of 
vaccination.
Since MAP is an intracellular organism, a Th1 response 
and in particular IFN-γ secretion has been thought to be 
suggestive of protection in PTB, similar to other mycobac-
terial infections [44]. However, studies reporting high IFN-
γ levels in vaccinated animals with high bacterial burden 
Table 2 Summary of post mortem findings
NIC: non infected control, IC: infected control, IVS: infected before vaccination, VSI: vaccinated before infection, SR: sacculus rotundus, VA: vermiform appendix, MUC: 
ileum and jejunum mucosa, ICV.IL: ileocecal valve and Ileum, MLN: mesenteric lymph node, NA: not analyzed.
a Gross pathology consisting of the following: pale white reactive spots and severe wall thickening (++) and increased vascularity and mild wall thickening (+).
Group Animal Gross pathologya Tissue qPCR GE/g Tissue culture
SR VA MUC SR VA MUC SR VA ICV.IL MLN
ST – – – – – – – – – –
NIC 0 – – – – – – – – – –
1 – – – – – – – – – –
2 – – – – – – – – – –
3 ++ ++ + 246 42.9 86.7 + + + +
IC 4 + ++ + – – 5.13 + + – –
5 + + – 620 – – – – – –
6 + + + – 37.8 – + + – –
7 + + – 200 105 6.27 + – – –
8 – – – – – – – – – –
IVS 9 – ++ – – – – – – – –
10 – – + – – 1130 – – – –
12 – – – – – – – – – –
13 – – – 1690 38.4 – – – – –
19 – – – – 258 2.45 + – – –
VSI 20 – – – NA – 7.16 – – – –
23 – – + – – – – + – –
24 – – – – – – – – – –
Figure 4 Bacteriology index per group. Bacteriology index was 
calculated based on the number of MAP qPCR positive tissues and 
the number of MAP culture positive tissues. IC: infected control, IVS: 
vaccinated after infection, VSI: vaccinated before infection. Error bars 
represent standard error of the mean. Significant differences were 
observed between the IC and IVS group (p = 0.034).
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and severe lesions [34–37] point out that IFN-γ may be 
a response to MAP antigens in circulating cells more 
than a correlate of protection. Recently humoral immune 
responses have shown to play key roles in protection in 
PTB [45] and against M. tuberculosis infection [46, 47]. 
Therefore, the increased level of antibodies in both vacci-
nated animal groups observed in our study could be in part 
responsible for the lower bacterial burden detected in the 
analyzed tissues. On the contrary, we did not observe an 
increased humoral response against MAP in the IC group 
probably because of the subclinical stage of the disease. In 
these animals the low antibody titers that they could be 
harboring may be forming immune complexes not detect-
able by ELISA or WB. In agreement, previous studies have 
shown low antibody titers during the first 2 years of infec-
tion, in naturally MAP infected cows [48].
In the present study, WB analysis was performed to 
better characterize host immune responses to vaccina-
tion and to identify potential markers that might be use-
ful in differentiating MAP vaccinated and MAP infected 
animals. Unfortunately the absence of humoral immunity 
in the IC group during the study period impeded predic-
tion of these hypothetical protein markers.
Although ELISA measures antibody levels against the 
PPA3 antigen and WB shows reactivity against all MAP 
extracted proteins, both techniques showed a strong corre-
lation when total reactivity in WB was compared to ELISA 
index values. At the individual protein level, WB analy-
sis showed some differences in humoral response among 
studied groups. For example, animals vaccinated before 
challenge had reactivity against ~12  kDa proteins which 
was absent in animals vaccinated after challenge. Animals 
vaccinated before challenge had higher reactivity against 
22, 35 and 75 kDa proteins compared to all animal groups. 
These changes were probably related to the intensity of 
humoral response, and to the fact that vaccination in the 
VSI group has had more time to develop. A previously 
characterized MAP lipoprotein of approximately 22  kDa 
(P22) has demonstrated the ability to induce humoral 
and cellular responses being detected in vaccinated sheep 
and in clinically and subclinically infected cows [49]. In 
our study, both vaccinated groups had reactivity against 
a ~22 kDa protein absent in infected animals which may 
suggest that in our subclinical experimental model the 
ability to stimulate the humoral response by infection may 
be more limited than in cows in field conditions.
Vaccination has been reported to be the best currently 
available tool to control PTB in field conditions in recent 
reviews [6, 50]. We have noted that both groups of vac-
cinated animals harbor fewer bacteria in tissues than 
non-vaccinated animals. However, other vaccination 
studies performed in a murine model have shown poor 
protection using the whole cell vaccine Silirum® [51], 
suggesting that the rabbit model could better emulate the 
effect of vaccination previously observed in ruminants.
Attending to the bacteriology index, we observed that 
vaccination after infection was more effective than vac-
cination before infection. Vaccination in older animals 
has been reported to induce better immune response 
[39], ameliorate the clinical disease [52, 53] improve milk 
production [10] and longevity [11, 54]. Although the clas-
sic recommendation to vaccinate animals before being 
infected has proven to be an effective approach in acute 
diseases, it might not be an effective strategy in chronic 
diseases. The goal of vaccination in acute diseases is to 
mimic natural infection and increase the specific immune 
response in order to enhance immunity and avoid the 
disease. However, the acquired immune response might 
be not sufficient to clear the infection in chronic diseases 
[55]. Furthermore, an increased immunity produced by 
vaccination in the clinical phase of the disease could have 
a beneficial effect and it could be used as a short term 
individual strategy to control the disease in high valued 
animals when vaccination of the whole flock is restricted.
In the present study we used a rabbit model, showing 
positive effects of whole-cell vaccination against MAP, 
increasing immune response and reducing bacterial load 
in tissues, and although some of the results presented 
here are in agreement with previous reports, these should 
be confirmed in a ruminant species. Mainly, because the 
differences observed in infection between both vaccina-
tion strategies could be in part influenced by the age of 
the animals and the period that the animals were under 
vaccination effects in each vaccination strategy (animals 
from the IVS group were vaccinated 2 months after ani-
mals of the VSI group meaning that in those 2 months the 
protective effect of vaccination could have decreased).
On the contrary to what may be traditionally believed, 
vaccination after infection has shown a slightly stronger 
protective effect than before infection. In any case, the 
protective mechanisms that operate behind MAP vac-
cination are unknown and further research is needed to 
understand why MAP infection progression and/or vac-
cination fail in some animals. In this case, rabbits can be 
a useful and non-expensive laboratory infection model 
to advance in the knowledge of MAP pathogenesis and 
vaccination.
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